Currently, the scale of cardiovascular disease patients in China has reached330 MillionThe demand in the泛vascular intervention market continues to grow rapidly, and "intervention without implantation" has become the mainstream trend in the industry. Biodegradable stents, which can gradually degrade and be absorbed after completing vascular repair without leaving permanent foreign objects, have become the preferred clinical solution.AMT Medical Inc. has become a benchmark enterprise in China in this field with its hardcore clinical data and full-field product layout.

In the field of biodegradable stents,AMT Medical Inc.The Only Company in the World to Have Both Fully Degradable Coronary Stents and Fully Degradable Peripheral Stents Enter Clinical TrialsThe enterprise boasts industry-leading core clinical data.Animal experiments show that its product can complete endothelialization in 2 weeks, rapidly repair the vascular intima, and significantly reduce the risk of acute and subacute thrombosis; the degradation period of coronary stents is about 3 years, and peripheral stents about 2.5 years, precisely matching the vascular repair cycle to avoid insufficient support or residual inflammation.

In a clinical trial of more than 200 coronary stents, a 6-year follow-up was achieved.0 Thrombus, with key indicators such as target lesion failure rate showing excellent performance, and long-term safety reaching world-class levels.Currently, the company's second-generation 3D-printed bioresorbable coronary and peripheral stents have both entered the special approval channel for innovative medical devices in China, with the potential to accelerate regulatory approval and market launch, seizing the commercialization opportunity for domestically produced bioresorbable stents.

At the same time,AMT Medical Inc. has built a complete matrix of implantable and interventional products, covering the full range of cardiovascular, peripheral vascular, neurovascular, and non-vascular fields.Currently, the company has obtainedFive registration certificates, including China's first domestically created stent positioner and carbon dioxide contrast injection device, the latter of which is free of nephrotoxicity, providing a safe contrast solution for patients with renal insufficiency or iodine allergy. It fills a gap in China and has entered the commercial scale-up phase. The R&D pipeline includes biodegradable intracranial stents and biodegradable biliary stents, continuously expanding into non-vascular interventional fields such as neurology and gastroenterology, forming a multi-indication, multi-scenario product portfolio.

——

Industry analysis believes that AMT Medical Inc.'s Series D financing round is a dual testament to the technological breakthroughs in China-produced high-end implantable and interventional devices and their recognition by capital markets.

Under the major industry trend of "intervention without implantation," with 3D-MAP additive manufacturing and self-developed PLCL material as its core barriers, and supported by globally leading clinical data, it is not only expected to become a leader in biodegradable vascular stents in China, but also to drive China's 3D-printed high-end medical devices from domestic substitution to global leadership.

As the registration of its core products advances and commercialization takes off, AMT Medical Inc. is poised to secure a significant position in the pan-vascular interventional market, offering safer and more advanced treatment options for patients with cardiovascular diseases. Medical Device News will continue to monitor the developments.